Literature DB >> 33493081

Current Overview of Obesity-Induced Lymphedema.

Christopher L Sudduth1, Arin K Greene1.   

Abstract

Significance: Obesity affects one-third of the U.S. population and lymphedema is a chronic disorder without a cure. The relationship between obesity and lymphedema has important implications for public health. Recent Advances: Extreme obesity can cause lower extremity lymphedema, termed "obesity-induced lymphedema (OIL)." OIL is a form of secondary lymphedema that may occur once an individual's body mass index (BMI) exceeds 40. The risk of lymphatic dysfunction increases with elevated BMI and is almost universal once BMI exceeds 60. Patients with OIL also may develop areas of massive localized lymphedema (MLL). Critical Issues: Individuals with OIL are in an unfavorable cycle of weight gain and lymphatic injury. As BMI increases lymphedema worsens, ambulation becomes more difficult, and BMI further rises. The fundamental treatment for OIL is weight loss. Resection of areas of MLL and lower extremity volume reduction are performed when the BMI is lowered to <40 to reduce complications and recurrence. Future Directions: The mechanisms by which obesity causes lymphedema are still being elucidated. Although lymphatic function can improve following weight loss, it is unclear whether lymphedema may be completely reversed.

Entities:  

Keywords:  body mass index; extremity; lymphedema; obesity

Mesh:

Year:  2021        PMID: 33493081     DOI: 10.1089/wound.2020.1337

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  2 in total

Review 1.  KATP channels in lymphatic function.

Authors:  Michael J Davis; Hae Jin Kim; Colin G Nichols
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-04       Impact factor: 5.282

Review 2.  Lymphatic Collecting Vessel: New Perspectives on Mechanisms of Contractile Regulation and Potential Lymphatic Contractile Pathways to Target in Obesity and Metabolic Diseases.

Authors:  Yang Lee; Scott D Zawieja; Mariappan Muthuchamy
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.